Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$11.99 USD

11.99
4,400,799

+0.03 (0.25%)

Updated Aug 23, 2024 03:59 PM ET

After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sundeep Ganoria headshot

FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs

by Sundeep Ganoria

On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

by Zacks Equity Research

Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.

Novavax (NVAX) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -45.60% and 8.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria headshot

Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.

Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

The latest trading day saw Novavax (NVAX) settling at $12.57, representing a -1.87% change from its previous close.

Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 15.15% and 5.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Sundeep Ganoria headshot

Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?

by Sundeep Ganoria

Novavax's (NVAX) shares continue to soar thanks to the recently signed partnership with Sanofi (SNY) to market its COVID-19 vaccine and develop novel COVID-19-influenza combination vaccines.

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Novavax (NVAX) have performed compared to their sector so far this year.

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Wall Street Bulls Look Optimistic About Novavax (NVAX): Should You Buy?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Novavax (NVAX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the most recent trading session, Novavax (NVAX) closed at $12.06, indicating a +1.34% shift from the previous trading day.

Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine

by Zacks Equity Research

Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.

Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

Novavax (NVAX) reachead $12.66 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.

Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod

by Zacks Equity Research

Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.

Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe

by Zacks Equity Research

Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NVAX) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

In the most recent trading session, Novavax (NVAX) closed at $14.06, indicating a +1.99% shift from the previous trading day.

Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.

Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal

by Zacks Equity Research

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.

Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal

by Zacks Equity Research

Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

by Zacks Equity Research

Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.